Imaging of Intracerebral Inflammation in MS
Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Dpa-714
What it measured
Main measures
Whole brain Binding Potential (BP) of 18F-DPA-714
D0
Brain volume lossSmouldering inflammation
Other measures (4)
Binding potential of 18F-DPA-714 in segmented brain regions
D0
MRI lesionsBinding potential of 18F-DPA-714 in subgroups of MS patients
D0
Predictive value of PET 18F-DPA-714 BP on neurological clinical metrics
2 years
Smouldering inflammationPredictive value of PET 18F-DPA-714 BP on MRI metrics
2 years
MRI lesionsBrain volume lossSmouldering inflammation
Who could take part
Relapsing and progressive · 18 to 65
Show the full criteria
Inclusion criteria
Healthy volunteers (group I, n=20) * Aged 18-65 years; * Able to understand the objectives and procedures of the study, and who give inform consent. Patients with relapsing-remitting MS (group II, n=15) * Aged 18-65 years * Clinically definite MS according to McDonald revised criteria * Less than 10 year of evolution * No clinical relapse during the past 3 months * Able to understand the objectives and procedures of the study, and who give inform consent Patients with progressive MS (group III and IV, n=15 per group) * Aged 18-65 years * Clinically definite MS according to McDonald revised criteria * SPMS evolving since more than 10 years for group III (n = 15). * PPMS evolving since less than 10 years for group IV (n=15). * Each progressive patient should have experienced a significant progression during the 2 years preceding the inclusion (with an estimated progression of the EDSS score of at least 0.5 point). * No clinical relapse during the past 3 months * Able to understand the objectives and procedures of the study, and who give inform consent.
Exclusion criteria
* Any reason, which does not allow performing MRI: claustrophobia, pace-maker or intra-ocular foreign body for example. * For women: pregnancy, lactation, lack of efficient contraception. At visit 2, a positive pregnancy test will lead to exclude the patient. * Uncontrolled diabetes * Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal pulmonary or cardiac disease. * Positive HIV test * Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual guidelines. * Other chronic neurological disease.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
In this study we plan to image the compartmentalized inflammation in MS using molecular imaging by positron emission tomography (PET) with a very highly resolutive camera. Two tracers will be studied and compared: i) [18F]DPA-714, which bind to the peripheral benzodiazepine receptor (PBR), a target mainly expressed by activated microglial cells. This new ligand for PBR displays several advantages compared to the existing reference compound PK11195 in term of brain entrance, signal to noise ratio, and radiolabelling possibility with [18F] ii) [18F]-fluoro-desoxy-glucose ([18F]FDG), which should reflect glucose metabolism in activated immune cells in the white matter. Progressive MS patients (secondary progressive and primary progressive) will be compared to relapsing-remitting patients and to healthy volunteers. All subjects will pass a complete neurological evaluation and a multimodal MRI to document clinical disability and tissue injury. A clinical and radiological follow up will then be performed for a 2-year period. This study should help to understand the contribution of the intracerebral inflammation on the progression of disability and could provide a surrogate marker for further therapeutic trials in chronic progressive MS.
Papers
Results
Peyronneau MA, Kuhnast B, Nguyen DL, Jego B, Sayet G, Caille F, Lavisse S, Gervais P, Stankoff B, Sarazin M, Remy P, Bouilleret V, Leroy C, Bottlaender M. [18F]DPA-714: Effect of co-medications, age, sex, BMI and TSPO polymorphism on the human plasma input function. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3251-3264. doi: 10.1007/s00259-023-06286-1. Epub 2023 Jun 9.Results
Ricigliano VAG, Louapre C, Poirion E, Colombi A, Yazdan Panah A, Lazzarotto A, Morena E, Martin E, Bottlaender M, Bodini B, Seilhean D, Stankoff B. Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis: A Retrospective Study. Neurol Neuroimmunol Neuroinflamm. 2022 Oct 13;9(6):e200026. doi: 10.1212/NXI.0000000000200026. Print 2022 Nov.Results
Garcia-Lorenzo D, Lavisse S, Leroy C, Wimberley C, Bodini B, Remy P, Veronese M, Turkheimer F, Stankoff B, Bottlaender M. Validation of an automatic reference region extraction for the quantification of [18F]DPA-714 in dynamic brain PET studies. J Cereb Blood Flow Metab. 2018 Feb;38(2):333-346. doi: 10.1177/0271678X17692599. Epub 2017 Feb 9.
Loading reviews and guidelines…
Related trials
- Glucose Consumption in MS Using [F-18]FDG-PET
Phase 4 · Recruiting
Still running
- Assessment of Synaptic Density in MS
Early phase 1 · Recruiting
Still running
- Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Inves
Not a drug-phase study · Status unknown
No results found
- Role of Microglial Activation and Norepinephrine Transporter Abnormali
Phase 1 / Phase 2 · Completed
Results posted, not judged
- PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Othe
Phase 1 / Phase 2 · Recruiting
Still running
- Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients
Status unknown
No results found
History
Started
Mar 2012
Main results due
Sept 2018
Finished
Sept 2018